Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)

China · Delayed Price · Currency is CNY

319.07

+12.00 (3.91%)

Aug 10, 2026, 4:00 PM EDT

SHA:688506 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,547	2,520	5,823	561.87	703.28	796.73
Revenue Growth	495.11%	-56.72%	936.31%	-20.11%	-11.73%	-21.33%
Gross Profit	2,279	2,261	5,539	319.61	465.58	593.34
Operating Income	-993.52	-800.69	3,686	-785.6	-329.83	-159.52
Net Income	-1,297	-1,054	3,708	-780.5	-282.38	-99.99
Earnings Per Share	-3.19	-2.61	9.25	-1.95	-0.78	-0.28
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
China	407.22	380.08
Overseas	-	2,124
Total	2,532	2,504

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	5,025	9,840	5,753	403.96	1,005	154.22
Total Debt	4,318	3,714	2,061	688.19	547.33	286.91
Net Cash (Debt)	706.95	6,126	3,692	-284.23	457.41	-132.69
Net Cash Growth	-15.57%	65.91%	-	-	-	-
Net Cash Per Share	1.74	15.18	9.21	-0.71	1.26	-0.37

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-1,050	-798.4	4,059	-615.35	-258.65	-135.03
Capital Expenditures	-324.5	-263.81	-83.86	-81.94	-34.56	-44.6
Free Cash Flow	-1,375	-1,062	3,975	-697.29	-293.21	-179.63
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	89.47%	89.72%	95.13%	56.88%	66.20%	74.47%
Operating Margin	-39.00%	-31.77%	63.31%	-139.82%	-46.90%	-20.02%
Pretax Margin	-37.64%	-28.63%	68.32%	-136.87%	-41.10%	-13.11%
Profit Margin	-50.91%	-41.81%	63.67%	-138.91%	-40.15%	-12.55%
FCF Margin	-53.98%	-42.15%	68.26%	-124.10%	-41.69%	-22.55%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	20.74	-	-	-
Forward PE	-	88.17	71.91	-	-	-
P/FCF Ratio	-	-	19.34	-	-	-
PS Ratio	51.72	52.93	13.20	99.85	-	-